One in three Asian-Americans surveyed in a recent poll report they had lost a family member due to complications of chronic hepatitis B.

However, about one in five respondents indicated they were not aware of the risks associated with the hepatitis B virus. Researchers believe these survey findings, outline the urgent need for more hepatitis B education in communities most prone to the deadly and communicable disease

Bill Gates has pledged $258.3 million for research and development to combat malaria, including funding for a test of the world's first vaccine against the mosquito-borne disease

Shire Pharmaceuticals Inc. presents new data demonstrating that the drug Adderall XR significantly improves symptoms in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).

Nearly 75-percent of study participants experienced improvement in ADHD symptoms, according to preliminary results of the Quality of Life, Effectiveness, Safety, and Tolerability (Qu.E.S.T.) study, presented at the annual meeting of Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD)

GlaxoSmithKline announces that the U.S. Food and Drug Administration (FDA) has approved Arranon (nelarabine) Injection, a chemotherapy agent, for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.

According to GlaxoSmithKline, this use is based on the induction of complete responses. Randomized trials demonstrating increased survival or other clinical benefit have not been conducted

Shire Pharmaceuticals Inc. unveils new data demonstrating highly prescribed children' drug Adderall significantly improves symptoms in adults with attention deficit-hyperactivity disorder (ADHD).

Nearly 75-percent of study participants experienced improvement in ADHD symptoms, according to preliminary results of the Quality of Life, Effectiveness, Safety, and Tolerability (Qu.E.S.T.) study, presented the data at the annual meeting of Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD)